by Kevin Robb | Nov 9, 2023
BlueRock Therapeutics has generated considerable media buzz with their announcement of positive Phase I clinical trial data on bemdaneprocel (BRT-DA01), an investigational, stem cell-derived, dopaminergic therapy for Parkinson’s disease. The trial is the result of...
by Stacey Johnson | Aug 22, 2023
It’s exciting news that there are close to 2,000 advanced therapies currently in clinical trials around the world. But is it good news? It’s exciting to see how far the cell and gene therapy (CGT) industry has come and how quickly the pipeline is growing. It’s...
by David Kent | Aug 22, 2023
As an academic researcher in the blood stem cell field for the last 20 years, I’ve been involved in a large number of interdisciplinary collaborations and, more recently, a series of industry partnerships. There is no doubt in my mind that cell and gene therapy is one...
by Cal Strode | Aug 16, 2023
In a wide-ranging interview with POLITICO reporter Robert King at the Next Generation of Health Care Therapies event, Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA), discussed cell and gene...
by Stephie Leung | Jul 20, 2023
A few months ago, I summarized seven local cell therapy companies in Canada that caught my attention. Since then, one full quarter of the financial calendar has passed. In the world of biotechnology start-ups, this could mean one more key milestone achieved, a new...
Comments